Bolt Biotherapeutics, Inc. (BOLT) Form 8-K — Aug 11, 2026

$BOLTForm 8-KItems 2.02, 9.01Filed Aug 11, 2026, 4:05 PM ET0001193125-26-344580Original filing

Bolt Biotherapeutics reported second quarter 2026 financial results and a business update in an 8-K dated August 11, 2026. The clinical-stage biotech is staking its future on BDC-4182, a claudin 18.2-targeting Boltbody ISAC in a Phase 1/2 study in gastric and gastroesophageal cancer, with initial clinical data expected alongside third quarter 2026 results. Second quarter collaboration revenue was $5,000 versus $1.8 million a year ago, while R&D expense fell to $5.1 million from $7.5 million and G&A fell to $2.4 million from $3.5 million, largely due to a prior restructuring. Net loss narrowed to $7.7 million, or $4.57 per share, from $8.6 million, or $4.46 per share, in Q2 2025.

Key figures

Eps: -$4.57 (Q2 2026 net loss per share, basic and diluted, vs -$4.46 in Q2 2025)
Revenue: $5,000 (Q2 2026 collaboration revenue vs $1.8 million in Q2 2025)
Net Income: -$7.72 million (Q2 2026 net loss, vs -$8.56 million in Q2 2025)
Total Assets: $40.3 million (as of June 30, 2026)
Cash Position: $18.1 million (cash, cash equivalents and marketable securities as of June 30, 2026)
Cash Runway: into 1Q 2027
Ga Expense Q2 2026: $2.4 million
Rnd Expense Q2 2026: $5.1 million
Stockholders Equity: $12.6 million (June 30, 2026, vs $26.5 million at Dec 31, 2025)
Net Loss Six Months2026: $15.0 million
Impairment Charges Q2 2026: $0.8 million
Weighted Avg Shares Q2 2026: 1,690,529
Loss From Operations Q2 2026: $8.4 million
Collaboration Revenue Q2 2025: $1.8 million

Price after filing

1 day: 0.0%7 days: -20.4%30 days: -7.8%

Close on the filing date to close N calendar days later (from $3.99). Historical, not a forecast.

AI analysis

Red flags5 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.